NASDAQ:ALZN Alzamend Neuro (ALZN) Stock Price, News & Analysis $1.02 -0.02 (-1.92%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$1.03 +0.01 (+1.47%) As of 04/3/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Alzamend Neuro Stock (NASDAQ:ALZN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Alzamend Neuro alerts:Sign Up Key Stats Today's Range$0.95▼$1.0550-Day Range$0.67▼$1.1952-Week Range$0.64▼$15.06Volume82,927 shsAverage Volume569,619 shsMarket Capitalization$6.73 millionP/E RatioN/ADividend YieldN/APrice Target$20.00Consensus RatingBuy Company OverviewAlzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.Read More… Remove Ads Alzamend Neuro Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreALZN MarketRank™: Alzamend Neuro scored higher than 70% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAlzamend Neuro has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAlzamend Neuro has only been the subject of 1 research reports in the past 90 days.Read more about Alzamend Neuro's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Alzamend Neuro are expected to decrease in the coming year, from ($1.68) to ($1.71) per share. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.91% of the float of Alzamend Neuro has been sold short.Short Interest Ratio / Days to CoverAlzamend Neuro has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alzamend Neuro has recently decreased by 47.02%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAlzamend Neuro does not currently pay a dividend.Dividend GrowthAlzamend Neuro does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.91% of the float of Alzamend Neuro has been sold short.Short Interest Ratio / Days to CoverAlzamend Neuro has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alzamend Neuro has recently decreased by 47.02%, indicating that investor sentiment is improving significantly. News and Social Media3.2 / 5News Sentiment0.74 News SentimentAlzamend Neuro has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Alzamend Neuro this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for ALZN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows4 people have added Alzamend Neuro to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Alzamend Neuro insiders have bought more of their company's stock than they have sold. Specifically, they have bought $13,069.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders30.21% of the stock of Alzamend Neuro is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions49.61% of the stock of Alzamend Neuro is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Alzamend Neuro's insider trading history. Receive ALZN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alzamend Neuro and its competitors with MarketBeat's FREE daily newsletter. Email Address ALZN Stock News HeadlinesShort Interest in Alzamend Neuro, Inc. (NASDAQ:ALZN) Drops By 47.0%March 30, 2025 | americanbankingnews.comIs Alzamend Neuro, Inc. (ALZN) the Cheapest Stock Insiders Are Buying In March?March 28, 2025 | insidermonkey.comTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 4, 2025 | Porter & Company (Ad)Alzamend Neuro CFO David Katzoff acquires $5,048 in common stockMarch 26, 2025 | investing.comAlzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer's Disease to take Place at Massachusetts General HospitalMarch 25, 2025 | globenewswire.comAlzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General HospitalMarch 18, 2025 | globenewswire.comAlzamend Neuro files to sell 75.775M shares of common stock for holdersMarch 14, 2025 | markets.businessinsider.comAlzamend Neuro announces initiation of Phase II trial of AL001March 12, 2025 | markets.businessinsider.comSee More Headlines ALZN Stock Analysis - Frequently Asked Questions How have ALZN shares performed this year? Alzamend Neuro's stock was trading at $1.16 at the beginning of the year. Since then, ALZN shares have decreased by 12.1% and is now trading at $1.02. View the best growth stocks for 2025 here. How were Alzamend Neuro's earnings last quarter? Alzamend Neuro, Inc. (NASDAQ:ALZN) issued its earnings results on Monday, March, 10th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.29) by $0.10. When did Alzamend Neuro's stock split? Shares of Alzamend Neuro reverse split before market open on Tuesday, July 16th 2024. The 1-10 reverse split was announced on Tuesday, July 16th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Alzamend Neuro IPO? Alzamend Neuro (ALZN) raised $12 million in an initial public offering (IPO) on Tuesday, June 15th 2021. The company issued 2,500,000 shares at $5.00 per share. Spartan Capital Securities, LLC acted as the underwriter for the IPO and -- was co-manager. How do I buy shares of Alzamend Neuro? Shares of ALZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Alzamend Neuro own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alzamend Neuro investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), Predictive Oncology (POAI), AST SpaceMobile (ASTS), NIO (NIO) and Ford Motor (F). Company Calendar Last Earnings3/10/2025Today4/03/2025Fiscal Year End4/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ALZN CIK1677077 Webwww.alzamend.com Phone844-722-6303FaxN/AEmployees4Year FoundedN/APrice Target and Rating Average Stock Price Target$20.00 High Stock Price Target$20.00 Low Stock Price Target$20.00 Potential Upside/Downside+1,860.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,950,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-289.14% Debt Debt-to-Equity RatioN/A Current Ratio3.80 Quick Ratio3.80 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($3.52) per share Price / Book-0.29Miscellaneous Outstanding Shares6,597,000Free Float4,860,000Market Cap$6.73 million OptionableNo Data Beta-0.01 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free Report This page (NASDAQ:ALZN) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTermination: 18F (read immediately)Have you ever heard of the government's 18F program? It helped manage digital services across the governmen...Altimetry | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alzamend Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alzamend Neuro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.